Compound class
GLP-1 and incretin compounds
Compounds that act on gut hormone receptors, from semaglutide to retatrutide.
Most compounds here are agonists of the GLP-1 receptor, such as semaglutide.1 Tirzepatide also acts on the GIP receptor,2 and cagrilintide is an amylin analogue.3 Tirzepatide is a once-weekly injection,2 orforglipron is a tablet,4 and eloralintide is still under development.5
GLP-1 and incretin agonists 8
-
Retatrutide
Triple agonist (GIP/GLP-1/Glucagon)
- Half-life
- About 6 days
- Given
- Once weekly in studies
- Form or status
- No product label among its sources
-
Tirzepatide
Dual GIP/GLP-1 agonist
- Half-life
- About 5 days
- Given
- Once weekly
- Form or status
- Has a US label
-
Dulaglutide
GLP-1 agonist
- Half-life
- About 5 days
- Given
- Once weekly
- Form or status
- Has a US label
-
Exenatide
GLP-1 agonist
- Half-life
- 2.4 hours (Byetta)
- Given
- Twice daily (Byetta); once every seven days (Bydureon BCise)
- Form or status
- Has a US label
-
Liraglutide
GLP-1 agonist
- Half-life
- About 13 hours
- Given
- Once daily
- Form or status
- Has a US label
-
Oral Semaglutide
GLP-1 agonist (oral tablet)
- Half-life
- Not stated
- Given
- Once daily in studies
- Form or status
- Has a US label
-
Orforglipron
Oral GLP-1 agonist (small molecule)
- Half-life
- About 29 to 49 hours
- Given
- Once daily
- Form or status
- Has a US label
-
Semaglutide
GLP-1 agonist
- Half-life
- About 1 week
- Given
- Once weekly
- Form or status
- Has a US label
Amylin and GLP-2 4
-
Cagrilintide
Amylin analog
- Half-life
- 159 to 195 hours (given with semaglutide)
- Given
- Once weekly in studies
- Form or status
- No product label among its sources
-
CagriSema
Amylin + GLP-1 blend
- Half-life
- Not stated
- Given
- Not stated
- Form or status
- Not stated
-
Eloralintide
Amylin analog
- Half-life
- Not stated
- Given
- Not stated
- Form or status
- No product label among its sources
-
Teduglutide (GLP-2)
GLP-2 analog
- Half-life
- About 2 hours
- Given
- Once daily
- Form or status
- Has a US label
Half-lives side by side
The figure each source gives, on one scale. Bars are ranges.
- Teduglutide (GLP-2)about 2 h
- Exenatide2.4 h, Byetta
- Liraglutideabout 13 h
- Orforglipronabout 29 to 49 h
- Dulaglutideabout 5 days
- Tirzepatideabout 5 days
- Retatrutideabout 6 days
- Cagrilintide159 to 195 h, with semaglutide
- Semaglutideabout 1 week
Log scale, 1 hour to about 3 weeks. Each figure and its source are in the list above. Minutes, days and weeks are turned into hours (1 day is 24 hours) only to place them on the scale. These are the sources' figures; the half-life the app uses to draw levels can differ.
Guides 11
- Cagrilintide dosage: mixing and units, alone or with GLP-1sCagrilintide doses, schedules and step-ups in the phase 1b, phase 2 and REDEFINE trials, and what the sources leave out: a label, a vial, storage.
- CagriSema dosage: combination doses studied in trialsCagriSema doses and escalation in trials, its regulatory status and the Wegovy label steps for semaglutide, with no mixing figures sourced.
- Dulaglutide dosage: pens, doses and schedulesUS and EU label doses for dulaglutide pens, the doses used in named trials, how it is given, missed doses and storage.
- Eloralintide dosage: mixing and syringe unitsInvestigational, with no labelled dose found. Trials gave it by subcutaneous injection, once weekly in the multiple-dose trials. No mixing steps found.
- Exenatide dosage: pens, doses and schedulesFor type 2 diabetes, the Byetta label starts at 5 mcg twice daily; Bydureon BCise gives 2 mg every 7 days. Label doses, trials, sites, storage.
- How to take orforglipron: what sources sayFoundayo (orforglipron) label strengths, once-daily dosing, dose steps, missed doses, storage and the doses used in the phase 2 and 3 trials.
- Liraglutide dosage: pens, doses and schedulesVictoza and Saxenda label doses and step-up schedules, pen strength, trial doses by arm and storage for liraglutide, each figure sourced.
- Oral semaglutide dosage: tablet strengths and schedulesOral semaglutide tablet strengths, the US and EU label step-up schedules, the doses trials used, how the tablet is taken and how it is stored.
- Retatrutide dosage and reconstitution: chart by vialRetatrutide has no label dose. Trial doses by arm, a U-100 syringe chart for the 10, 20 and 30 mg powder vials people log, and what is known about storage.
- Semaglutide dosage: chart, units and compounded vialsWegovy and Ozempic label doses, the STEP 1 and STEP 5 schedules, and how a mg dose becomes mL and units on a U-100 syringe from a compounded vial.
- Tirzepatide dosage: label doses, ready vials and unitsUS tirzepatide labels start at 2.5 mg once weekly, with 2.5 mg steps after at least 4 weeks on a dose, up to 15 mg in adults. Trials, vials, storage.
Calculators 6
- Cagrilintide dosage calculator and chartUnits on a U-100 syringe for cagrilintide: enter the powder in your vial, the water you add and your dose, in mg or mcg, to see the mark.
- CagriSema reconstitution calculator: vials, water and unitsUnits on a U-100 syringe for CagriSema: enter the powder in your vial, the water you add and your dose, in mg or mcg, to see the mark.
- Liraglutide calculator: mL and syringe unitsmL and syringe units for liraglutide from the mg per mL printed on the vial: enter the concentration and your dose to see the mark.
- Retatrutide reconstitution calculator: 10 to 30 mg vialsUnits on a U-100 syringe for retatrutide: enter your vial, water and dose, or print the chart for 10, 15, 20 and 30 mg vials.
- Semaglutide reconstitution calculator by vialUnits on a U-100 syringe for semaglutide: enter the powder in your vial, the water you add and your dose, in mg or mcg, to see the mark.
- Tirzepatide reconstitution calculator by vialUnits on a U-100 syringe for tirzepatide: enter your vial, water and dose, or print the chart for 10, 20, 30 and 60 mg vials.
Compare 4
- Oral semaglutide vs orforglipronOral semaglutide and orforglipron compared on what each pill is, the tablets, label half-life, labelled and trial doses and status, with sources.
- Retatrutide vs semaglutideRetatrutide and semaglutide compared on receptors, half-life, studied doses and approval status, with each figure tied to its own trial or label.
- Retatrutide vs tirzepatideRetatrutide and tirzepatide compared on receptors, half-life, studied doses and approval status, with each figure tied to its own trial or label.
- Semaglutide vs tirzepatideSemaglutide and tirzepatide compared on how they act, half-life, labelled doses and the two large trials that compared them, with every figure sourced.
Logged in Milligram
Share of people who logged a dose in Milligram in the 90 days to 15 November 2026 who logged each compound.
Retatrutide, how often
Tirzepatide, how often
How often: among people with three or more logged doses, by the average gap between their doses.
Aggregated and anonymous, shares of people only. Each compound not listed: too few people logged it to show a share. It describes what people set up in the app, not advice on what to take.
References 15
- Novo Nordisk Pharmaceutical Industries, LP. OZEMPIC (semaglutide) injection, for subcutaneous use. Prescribing information, Novo Nordisk. 2026. DailyMed label
- Eli Lilly and Company. MOUNJARO (tirzepatide) injection, for subcutaneous use. Prescribing information, revised August 2026. 2026. DailyMed label
- Lau DCW, Erichsen L, Francisco AM, Satylganova A, le Roux CW, McGowan B, Pedersen SD, Pietiläinen KH, Rubino D, Batterham RL. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. 2021. PMID 34798060
- Eli Lilly and Company. FOUNDAYO (orforglipron) label, version 10. 2026. DailyMed label
- Bhattachar S, et al. Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept. 2026. PMC12992164
- Urva S, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet 2022. PMID 36354040
- Jastreboff AM, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med 2026. PMID 42814954
- Eli Lilly and Company. Trulicity (dulaglutide) injection, for subcutaneous use. US prescribing information, DailyMed version 62, 2026. DailyMed label
- AstraZeneca Pharmaceuticals LP. Byetta (exenatide) injection, for subcutaneous use. US prescribing information, DailyMed version 26, 2025. Byetta label
- Bydureon BCise (exenatide extended-release) injectable suspension, for subcutaneous use. US prescribing information, FDA label supplement 209210s025, 2025. Bydureon BCise label
- VICTOZA (liraglutide) injection, for subcutaneous use. Prescribing information. Novo Nordisk, 2025. DailyMed label
- Aroda VR, et al. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care 2019;42(9):1724-1732. PMID 31186300
- Novo Nordisk. Rybelsus (semaglutide) tablets and Ozempic (semaglutide) tablets, for oral use. US prescribing information, DailyMed record, version 14, 2026. DailyMed label (Rybelsus and Ozempic tablets)
- Enebo LB, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet 2021. PMID 33894838
- Takeda Pharmaceuticals America. Gattex (teduglutide) for injection, for subcutaneous use. US prescribing information, DailyMed version 20, 18 September 2025. DailyMed label
Each figure is as the compound's own sources give it, numbered under References. Where they give none, the list says not stated. The half-life the app draws levels with can differ. Reviewed 17 November 2026.